Company / Accounts Receivable
Edwards Lifesciences Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$659.6M
FY2025
5-year range
$582.2M / $775.1M
FY2021-FY2025
Trend
+8.3%
vs FY2024
Sector context
#36 of 138
Health Care
What the data says
At $660M, Edwards Lifesciences's accounts receivable ranks #36 of 138 in the Health Care sector. Accounts Receivable has fluctuated over the past 10 years, ranging from $366M in FY2016 to $775M in FY2023.
Based on SEC 10-K filings.
$660M in FY2025 with a 5-year CAGR of +5.1%.
Declined from $775M to $660M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +0.9%
- 5-Year CAGR
- +5.1%
- 10-Year CAGR
- -
Sector benchmark
#36 of 138 in Health CareTop 26% of 138This company $659.6M Sector average $1.3B
▼
-50.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.1%, indicating consistent growth.
- In FY2025, accounts receivable increased 8.3% year-over-year.
- Ranks #36 out of 138 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $659.6M | +8.3% |
| FY2024 | $609.1M | -21.4% |
| FY2023 | $775.1M | +20.5% |
| FY2022 | $643.0M | +10.4% |
| FY2021 | $582.2M | +13.1% |
| FY2020 | $514.6M | -5.3% |
| FY2019 | $543.6M | +19.0% |
| FY2018 | $456.9M | +4.1% |
| FY2017 | $438.7M | +20.0% |
| FY2016 | $365.5M | +15.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026